| scholarly article | Q13442814 |
| P50 | author | Jeanette H Leusen | Q57039110 |
| P2093 | author name string | Matthias Peipp | |
| Jan G J van de Winkel | |||
| Thomas Valerius | |||
| Thomas Beyer | |||
| Stefanie Derer | |||
| Katja Klausz | |||
| Michael Dechant | |||
| Stefan Lohse | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 3770-3778 | |
| P577 | publication date | 2011-02-11 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing | |
| P478 | volume | 186 |
| Q35992488 | 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. |
| Q36366594 | Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. |
| Q34000700 | Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). |
| Q35817552 | Building better monoclonal antibody-based therapeutics. |
| Q36127055 | Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. |
| Q39027573 | Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. |
| Q95277068 | Efficient N-Glycosylation of the Heavy Chain Tailpiece Promotes the Formation of Plant-Produced Dimeric IgA |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q39358478 | Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells |
| Q35860685 | Exploitation of the Polymeric Immunoglobulin Receptor for Antibody Targeting to Renal Cyst Lumens in Polycystic Kidney Disease |
| Q38239286 | Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer |
| Q38029985 | Fc-fusion proteins: new developments and future perspectives. |
| Q64097340 | Function and dysfunction of plasma cells in intestine |
| Q41704272 | Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy |
| Q39114924 | IgA EGFR antibodies mediate tumour killing in vivo |
| Q33619979 | IgE-based immunotherapy of cancer: challenges and chances |
| Q37892323 | Immunoglobulin A: A next generation of therapeutic antibodies? |
| Q36487349 | Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. |
| Q51065170 | Impaired migration of IgA-secreting cells to colon adenocarcinomas. |
| Q91989462 | Influence of media composition on recombinant monoclonal IgA1 glycosylation analysed by lectin-based protein microarray and MALDI-MS |
| Q43177854 | Insights from Fc receptor biology: a route to improved antibody reagents |
| Q88943760 | Monoclonal antibody-mediated killing of tumour cells by neutrophils |
| Q46027197 | Myeloid cells as effector cells for monoclonal antibody therapy of cancer. |
| Q35569901 | Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life |
| Q47114808 | Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases |
| Q37964490 | Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. |
| Q52648924 | Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. |
| Q37936765 | Structure and function relationships in IgA. |
| Q34218284 | The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity |
| Q38254478 | Upstream and downstream processing of recombinant IgA. |
| Q42558684 | Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology? |
Search more.